Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ling

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology in Drug Development|January 23, 2025
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral AdministrationRenu Singh, Mark Shelton, Isabel Olson, et al.
Clinical Pharmacology and Therapeutics|March 24, 2018
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or CarbamazepineJustin D Lutz, Brian J Kirby, Lu Wang, et al.
Journal of Clinical Pharmacology|April 29, 2026
Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and LenacapavirJing Niu, Haeyoung Zhang, John Ling, et al.
Clinical Pharmacology and Therapeutics|March 24, 2018
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose RifampinJustin D Lutz, Brian J Kirby, Lu Wang, et al.
Journal of Lipid Research|January 20, 2004
Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometryAllan Weber, Jinsong Ni, Kah-Hiing John Ling, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy SubjectsErik Mogalian, Polina German, Brian P Kearney, et al.
Analytical Biochemistry|January 28, 2021
Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studiesDeqing Xiao, Kah Hiing John Ling, Thomas Tarnowski, et al.
Journal of Clinical Pharmacology|May 29, 2026
A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and LenacapavirHaeyoung Zhang, Steve West, Nerissa Kwok, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 22, 2022
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, John Ling, Jianhong Wang, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology in Drug Development|January 23, 2025
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral AdministrationRenu Singh, Mark Shelton, Isabel Olson, et al.
Clinical Pharmacology and Therapeutics|March 24, 2018
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or CarbamazepineJustin D Lutz, Brian J Kirby, Lu Wang, et al.
Journal of Clinical Pharmacology|April 29, 2026
Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and LenacapavirJing Niu, Haeyoung Zhang, John Ling, et al.
Clinical Pharmacology and Therapeutics|March 24, 2018
Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose RifampinJustin D Lutz, Brian J Kirby, Lu Wang, et al.
Journal of Lipid Research|January 20, 2004
Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometryAllan Weber, Jinsong Ni, Kah-Hiing John Ling, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy SubjectsErik Mogalian, Polina German, Brian P Kearney, et al.
Analytical Biochemistry|January 28, 2021
Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studiesDeqing Xiao, Kah Hiing John Ling, Thomas Tarnowski, et al.
Journal of Clinical Pharmacology|May 29, 2026
A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and LenacapavirHaeyoung Zhang, Steve West, Nerissa Kwok, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 22, 2022
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, John Ling, Jianhong Wang, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Pageof 6